Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies

Feng, Dechao; Yang, Yubo; Wang, Zhenghao; Wei, Wuran; Li, Li

doi:10.21037/tau-20-1358

Cited by 13 publications

(10 citation statements)

References 38 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the PCA risk does not increase significantly, which is consistent with the results of previous epidemiological studies (19,20). Indeed, the chronic CDH disorder caused by staying up or night-shift work might increase PCA risk through other factors, such as metabolic syndrome and inflammatory bowel disease (72)(73)(74)(75)(76)(77). There can be no denying that gene expression signatures are subject to sampling bias caused by intratumor genetic heterogeneity.…”

Section: Discussionsupporting

confidence: 84%

Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

BackgroundCurrently, the impact of the circadian rhythm on the tumorigenesis and progression of prostate cancer (PCA) has yet to be understood. In this study, we first established a novel nomogram to predict PCA progression based on circadian clock (CIC)-related genes and provided insights into the tumor immune microenvironment.MethodsThe TCGA and Genecards databases were used to identify potential candidate genes. Lasso and Cox regression analyses were applied to develop a CIC-related gene signature. The tumor immune microenvironment was evaluated through appropriate statistical methods and the GSCALite database.ResultsTen genes were identified to construct a gene signature to predict progression probability for patients with PCA. Patients with high-risk scores were more prone to progress than those with low-risk scores (hazard ratio (HR): 4.11, 95% CI: 2.66-6.37; risk score cut-off: 1.194). CLOCK, PER (1, 2, 3), CRY2, NPAS2, RORA, and ARNTL showed a higher correlation with anti-oncogenes, while CSNK1D and CSNK1E presented a greater relationship with oncogenes. Overall, patients with higher risk scores showed lower mRNA expression of PER1, PER2, and CRY2 and higher expression of CSNK1E. In general, tumor samples presented higher infiltration levels of macrophages, T cells and myeloid dendritic cells than normal samples. In addition, tumor samples had higher immune scores, lower stroma scores and lower microenvironment scores than normal samples. Notably, patients with higher risk scores were associated with significantly lower levels of neutrophils, NK cells, T helper type 1, and mast cells. There was a positive correlation between the risk score and the tumor mutation burden (TMB) score, and patients with higher TMB scores were more prone to progress than those with lower TMB scores. Likewise, we observed similar results regarding the correlation between the microsatellite instability (MSI) score and the risk score and the impact of the MSI score on the progression-free interval. We observed that anti-oncogenes presented a significantly positive correlation with PD-L1, PD-L2, TIGIT and SIGLEC15, especially PD-L2.ConclusionWe identified ten prognosis-related genes as a promising tool for risk stratification in PCA patients from the fresh perspective of CIC.

show abstract

Section: Discussionsupporting

confidence: 84%

Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…standardized incidence ratio (SIR) of bladder cancer in CD patients, but not in UC patients (114). Additional analysis has found the CD bladder cancer risk to be only marginal at an SIR of 1.19 (115)(116)(117). Notably, patients with IBD have an increased risk of renal cell carcinoma (RCC); however, they are known to be diagnosed at a younger age with earlier tumor stage and have favorable outcomes compared to the general population (115,118).…”

Section: Cancers With No Proven Association With Ibdmentioning

confidence: 99%

“…Additional analysis has found the CD bladder cancer risk to be only marginal at an SIR of 1.19 (115)(116)(117). Notably, patients with IBD have an increased risk of renal cell carcinoma (RCC); however, they are known to be diagnosed at a younger age with earlier tumor stage and have favorable outcomes compared to the general population (115,118). It is theorized that more frequent imaging of the abdomen may contribute to higher rates of early recognition and incidental findings of renal malignancy in patients with IBD.…”

Section: Cancers With No Proven Association With Ibdmentioning

confidence: 99%

“…Immunosuppressive or biologic therapy for IBD is not associated with worse outcomes in RCC patients; however, thiopurines are associated with higher rates of developing kidney and urinary tract cancers and should be avoided in these patients (118)(119)(120). No relationship between IBD and male genital cancers has been established (115,117). Given the marginal relationship with IBD and early detection for urinary tract cancers, it is reasonable to approach treatment using the guidelines applicable to the general population, with special attention to IBD therapy choice during treatment.…”

Section: Cancers With No Proven Association With Ibdmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review

Bodofsky¹,

Freeman²,

Hong³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), subdivided into Crohn's disease (CD) and ulcerative colitis (UC), is an auto-inflammatory gastrointestinal condition with an established increased risk of certain malignancies. Compared to sporadic cancers in the general population, IBD-associated malignancies present unique challenges to providing quality care. Radiation therapy (RT) targeting IBD-associated malignancies may directly impact inflamed bowel, with special considerations for the risk of toxicities. Historically, patients with IBD have been less likely to receive radiotherapy in proximity to bowel due to a poor understanding of the potential for acute and chronic toxicities and unclear treatment outcomes. We present a scoping review, to more fully assess IBD-associated malignancies and their treatment. As opposed to a systematic review, this approach allows us to analyze the broadest range of literature, including experimental and non-experimental research, and reflect on current guidelines and practices.Methods: Literature search: a systematic, scoping search of published literature was conducted using applicable PRISMA scoping review (ScR) guidelines. The literature search was conducted on PubMed and was searched systematically by screening all publications from January 1990 to June 2021. Citations from the included articles were also manually searched. Relevant National Comprehensive Cancer Network guidelines were reviewed. Final query was December 2021 in editing. Articles were selected for full text reading if the abstract reported on malignancy in IBD or bowel toxicities. Results:The pelvic malignancies found in the IBD patient population, including colorectal carcinoma, anal carcinoma, lymphoma, small bowel adenocarcinoma (SBA), and prostate cancer (PCa) are outlined in this scoping review. Additional cancers that have a contested relationship with IBD, including cervical, bladder, and upper GI cancers, are also explored. This review provides literature guided recommendations on the eligibility of patients with IBD to receive RT, management of IBD during and after treatment, and counseling for radiation-induced toxicities.Conclusions: After review of the literature, IBD should not be considered an absolute contraindication to radiation therapy, given the lack of evidence for increased toxicities, and the evolution of RT techniques which limit radiation dose to the bowel.

show abstract

“…By 2030, approximately 20% of the world’s population will be aged 65 or older, with an exponential augmentation in the prevalence of prostate cancer (PCa) because this disease is most common in men 65 and older [ 2 , 3 ]. Moreover, the prevalence of metabolic disorders apparently increases and further facilitates the morbidity and mortality of PCa [ 4 , 5 ]. PCa has the highest morbidity and mortality among urothelial malignancies, with an estimated 1.4 million new male cases and 375,000 deaths worldwide in 2020 [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer

Feng

Shi

et al. 2022

J Transl Med

Self Cite

View full text Add to dashboard Cite

Background Senescent cells have been identified in the aging prostate, and the senescence-associated secretory phenotype might be linked to prostate cancer (PCa). Thus, we established a cellular senescence-related gene prognostic index (CSGPI) to predict metastasis and radioresistance in PCa. Methods We used Lasso and Cox regression analysis to establish the CSGPI. Clinical correlation, external validation, functional enrichment analysis, drug and cell line analysis, and tumor immune environment analysis were conducted. All analyses were conducted with R version 3.6.3 and its suitable packages. Results We used ALCAM and ALDH2 to establish the CSGPI risk score. High-risk patients experienced a higher risk of metastasis than their counterparts (HR: 10.37, 95% CI 4.50–23.93, p < 0.001), consistent with the results in the TCGA database (HR: 1.60, 95% CI 1.03–2.47, p = 0.038). Furthermore, CSGPI had high diagnostic accuracy distinguishing radioresistance from no radioresistance (AUC: 0.938, 95% CI 0.834–1.000). GSEA showed that high-risk patients were highly associated with apoptosis, cell cycle, ribosome, base excision repair, aminoacyl-tRNA biosynthesis, and mismatch repair. For immune checkpoint analysis, we found that PDCD1LG2 and CD226 were expressed at significantly higher levels in patients with metastasis than in those without metastasis. In addition, higher expression of CD226 significantly increased the risk of metastasis (HR: 3.65, 95% CI 1.58–8.42, p = 0.006). We observed that AZD7762, PHA-793887, PI-103, and SNX-2112 might be sensitive to ALDH2 and ALCAM, and PC3 could be the potential cell line used to investigate the interaction among ALDH2, ALCAM, and the above drugs. Conclusions We found that CSGPI might serve as an effective biomarker predicting metastasis probability and radioresistance for PCa and proposed that immune evasion was involved in the process of PCa metastasis.

show abstract

Inflammatory bowel disease and risk of urinary cancers: a systematic review and pooled analysis of population-based studies

Cited by 13 publications

References 38 publications

Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer

Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer

Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review

A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer

Contact Info

Product

Resources

About